WASHINGTON — In a stunning development that defies both medical science and basic economics, the Food and Drug Administration yesterday announced it would consider a patient’s ability to pay before approving certain cancer treatments. The new policy, titled ‘Patient Financial Readiness Assessment Framework,’ reportedly will evaluate not just a drug’s safety and efficacy, but also whether the patient has sufficient income to afford it before it can be prescribed.
‘This is a transformative step in healthcare equity,’ FDA Commissioner Robert Califf told a packed room at the agency’s headquarters. ‘No longer will we approve treatments that patients simply cannot access. Now, if you can’t afford your medicine, we won’t approve it for you. It’s not that we’re denying access — it’s that we’re requiring upfront financial clearance.’
WASHINGTON — In a move that will fundamentally alter the American landscape of professional networking, the Department of Health and Human Services announced yesterday that all pharmaceutical sales representatives must now submit a 47-point digital receipt trail for every complimentary coffee, bagel, or lukewarm espresso drink consumed while pitching new drug formulations to physicians.
The new rule, codified in a 192-page directive titled “Sunshine Receipt Enhancement Act of 2026,” requires that each transaction be logged within 3.2 minutes of consumption, uploaded to the federal compliance portal, and include three original photos of the receipt, a geolocation stamp, and a notarized statement from the sales rep confirming the coffee was indeed complimentary and not a self-purchased latte they happened to purchase before walking into the doctor’s office.
MINNEAPOLIS — The moment your implanted pacemaker starts emitting audible screams at 3:17 a.m. is not a medical emergency. It is, according to MedTech Innovations Inc. Customer Care Liaison Sarah Jenkins (who also handles PR for the company’s quarterly earnings presentations), a “scheduling conflict” that will be resolved through “administrative triage.”
My name is Phil Kovacs, and for fifteen years I told doctors how great their pacemakers were while earning commissions on every unit sold. When my conscience eventually returned to me—despite management warning that returning ethical principles was the worst ROI of my career—I found out the first rule of medical device bureaucracy: you do not call to report a malfunction; you file a Request for Reclassification Form 8B-Δ.
WASHINGTON, D.C. — The FDA’s new biosimilar pricing transparency initiative, announced last Tuesday with the solemn gravitas of a coroner reading a death certificate, has inadvertently created the administrative equivalent of a hamster trapped in a centrifuge. According to preliminary industry estimates, what was once a straightforward 48-hour insurance pre-authorization process for a generic biosimilar antibody has now evolved into a multi-departmental approval marathon requiring coordination between the FDA’s Division of Biologics Review, the CMS Drug Pricing Office, the Department of Consumer Affairs’ Pharmacy Benefit Unit, and what is reportedly being referred to internally as “The Office of Bureaucratic Friction.”
NEW YORK — The algorithm knows your heart rate before you can text your doctor. That’s what happens when a pharmaceutical sales rep’s conscience is replaced by a neural net trained on 14 years of rejected claims and 73,000 hours of “customer education” at local grocery store pharmacies.
Last month, I received an email from my insurer’s AI department telling me that my claim for a basic flu shot would be denied until I uploaded three months of “lifestyle compliance data” to their secure portal. The data includes my sleep tracker readings, gym check-in logs, and a live stream of my morning coffee ritual. I’m not a bad person. I work in healthcare. But the math is clear: if you’re living below a 7.2 on their Wellness Index, your claim won’t process.
It’s 7:43 AM. You’re groggy, holding a half-empty cup of coffee, and you’re just trying to remember if you already ate breakfast today. Then you see the pill bottle on your nightstand.
The medication hasn’t changed. The company logo looks the same. The price tag is still that eye-watering $245 for a 30-day supply.
But something has fundamentally altered.
Now, every time you ingest that pill, you must first verify your metabolic status has been approved by the FDA, the EPA, the CDC, your state’s Department of Public Health, and the newly formed Department of Glycemic Stability Compliance.
MONTGOMERY, AL — For the first time in healthcare history, a man in a wheelchair could be denied an ambulance because the AI billing system calculated his mood score was too low for the weather.
That’s not hyperbole. That’s a real algorithm now used by three Midwest hospital systems to determine who gets transport to the ER and who gets to walk there themselves.
According to Dr. Marcus Chen, chief medical informatics officer at St. Jude’s Regional Medical Center:
WASHINGTON — In a stunning move that healthcare economists are calling “brilliant,” the Pharmacy Benefit Manager Association has announced that starting immediately, kickback payments to doctors will no longer be delivered via wire transfer, but rather as limited-edition NFTs of the drugs they recommend.
“The transition to digital-asset kickbacks is a quantum leap forward for our industry,” said Dr. Marcus Wellington, Chief Physician Liaison for PBM ChainLink, speaking beside a holographic sculpture of a blister pack on a black marble table in New York. “Imagine the future: your cardiologist promotes Nexium™, and receives an NFT of a proton-pump inhibitor you will never use because your plan prefers Omeprazole™ — the generic that you can only afford by signing a five-year non-disclosure agreement.”
MAY 20, 2026 — The FDA announced today that two new cancer treatments have been approved: Bizengri for NRG1 fusion-positive cholangiocarcinoma and Enhertu for early HER2-positive breast cancer. But before patients can receive these life-saving medications, they must first navigate a compliance labyrinth that threatens to cost more than the drugs themselves.
Bizengri: The $499,999 Hope
Bizengri (zenocutuzumab-zbco) has been approved as the first FDA-authorized treatment for unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma that has progressed after prior therapies. This rare subtype of bile duct cancer affects fewer than 500 patients annually, yet the approval documentation requires:
SAN FRANCISCO — If your insulin was last priced based on how many TikTok videos you watched about carbohydrates, you’re not alone. According to Pfizer’s new “Engagement-Based Pricing Algorithm,” your medication costs now fluctuate weekly based on social media traffic.
“I’ve developed an algorithm that monitors TikTok, Instagram, and YouTube for carbohydrate content,” said Dr. Kevin Murphy, Pfizer’s Vice President of Dynamic Pricing and Social Sentiment Analysis. “Last week, when TikTok users posted 14% fewer dance videos about oatmeal and 23% more about keto diets, we adjusted insulin prices downward accordingly. This week, however, when viral videos about carb-loading for a marathon went viral, we increased prices by 8.2%.”
NEW YORK — In an unprecedented move that will redefine the American healthcare system, major insurers have officially begun denying claims for patients who exhibit “predictive anxiety” about developing conditions that have not yet manifested. According to the newly released 2026 Prior Authorization Guidelines, insurance companies are now justified in refusing coverage for individuals who:
- Have been diagnosed with a genetic predisposition to certain cancers but have never tested positive
- Experience “anticipatory worry” about developing rare conditions
- Ask questions that demonstrate they understand their own medical risks
- Express concern about the very real possibility of falling ill
“This is a natural evolution of the healthcare system,” explained Dr. Jennifer Mordant of the National Institute of Insurance Innovation. “Why should we pay for services that might not be needed? Our new AI-powered denial algorithms can predict illness before the symptoms appear, and if the patient shows enough concern about the prediction, that’s sufficient evidence of need.”